Posters & Publications

Paxalisib SABCS 2025: Liquid Biopsy Tracking of PI3K–mTOR Residual Disease Signatures in Metastatic HER2+ Breast Cancer

Paxalisib SABCS 2025: A phase 1b, multi-centre, open-label, randomized study to evaluate the safety, tolerability, and clinical activity of combining paxalisib with olaparib or pembrolizumab/chemotherapy in patients with advanced breast cancer

Depleting the action of EZH2 through PI3K-mTOR inhibition to overcome metastasis and immunotherapy resistance in triple-negative breast cancer

EVT801 Presentation at the 15th Biennial Ovarian Cancer Research Symposium

EVT801 Phase 1 clinical trial poster presentation at AACR 2024

EVT801 Phase 1 biomarker analysis poster presentation at AACR 2024

EVT801 Phase 1 clinical trial poster presentation from ESMO 2023

EVT801 Phase I Clinical Trial poster presented at AACR23

Poster at Int. Congress of the Society for Melanoma Research

Paxalisib phase II study poster presented as ASCO 2022

Paxalisib poster presented at SNO (virtual meeting)

Paxalisib poster presented at AACR (virtual meeting)

Paxalisib poster presented at ASCO (virtual meeting)

Ellingson et al (2020) - multiparametric MR-PET in GDC-0084 P1

Wen et al (2020) GDC-0084 phase 1 in glioblastoma

GDC-0084 Poster presented at EANO (Lyon, France)

Ippen et al (2019) - GDC-0084 in brain mets (prelinical)

GDC-0084 Poster presented at SNO

Salphati et al (2016) - Brain Distribution and Efficacy of GDC-0084

GDC-0084 Poster presented at ASCO

GDC-0084 Poster presented at ASCPT

Heffron et al (2016) - Development of GDC-0084